Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Englewood, New Jersey Clinical Trials

A listing of Englewood, New Jersey clinical trials actively recruiting patient volunteers.

RESULTS

Found (294) clinical trials

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.  This investigational intervention treatment uses a single biological drug and is conducted in two parts. Part 1: INCAGN02385 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose ...

Phase

3.71 miles

Learn More »

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with advanced malignancies. This investigational intervention treatment uses a single biological drug and is conducted in two parts. Part 1: INCAGN02390 at the protocol-defined starting dose administered every 2 weeks (Q2W), with ...

Phase

3.71 miles

Learn More »

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

This study evaluates the safety of abemaciclib in combination therapies (letrozole, anastrozole, tamoxifen, exemestane, exemestane plus everolimus, trastuzumab, LY3023414 plus fulvestrant, pertuzumab plus trastuzumab with loperamide) for breast cancer that has spread to other parts of the body.

Phase

4.05 miles

Learn More »

Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer

During the Phase 1 segment, the dose and regimen of MGCD516 will be assessed. During the Phase 1b segment, the clinical activity of MGCD516 will be evaluated in selected patient populations. Patients anticipated to be enrolled in Phase 1b will be selected based upon the following cancer diagnosis: Non-small cell ...

Phase

4.05 miles

Learn More »

A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

This is a four-part trial. In Part 1, subjects will be enrolled to successive cohorts to determine the maximum tolerated dose (MTD). Dose escalation decision will be made based on DLTs that occur after the first dose of ASP2215 during remission induction. The treatment will consist of three distinct periods: ...

Phase

4.05 miles

Learn More »

A Study Evaluating the Safety Pharmacokinetics and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)

This is an open-label, Phase 1, dose-escalation study to determine the maximum tolerated dose (MTD) and the recommended phase two dose (RPTD), and to assess the safety, preliminary efficacy, and pharmacokinetic (PK) profile of ABBV-321 for participants with advanced solid tumors likely to overexpress the epidermal growth factor receptor (EGFR). ...

Phase

4.05 miles

Learn More »

The Healthy Life Choices Project in HIV-Positive Patients

This is a Phase I trial (a study to evaluate effectiveness in a small number of patients). Patients will be randomized (like tossing a coin) to 1 of 2 groups: Group 1: Patients will go on a specific diet and will be taught new behavior skills. Group 2: Patients will ...

Phase

4.05 miles

Learn More »

We are looking for adults 18 years of age and older with hypoparathyroidism (at time of consent) to take part in a clinical research study. The purpose of the PARALLAX Study is to measure the safety and tolerability of an injectable study drug and its effects on calcium levels in ...

Phase

4.05 miles

Learn More »

Topotecan in Treating Patients With Refractory or Progressive Primary Malignant Brain Tumors

OBJECTIVES: - Evaluate the safety and effectiveness of convection enhanced delivery (intracerebral clysis [ICC]) therapy comprising topotecan hydrochloride in patients with refractory or progressive primary malignant brain tumors. - Apply advanced MRI as a noninvasive means of optimizing treatment parameters and determining volume of drug distribution with convection enhanced delivery. ...

Phase

4.05 miles

Learn More »

A Phase 1 Multiple Ascending Dose Study of DS-3032b an Oral Murine Double Minute 2 (MDM2) Inhibitor in Subjects With Advanced Solid Tumors or Lymphomas

This will be a Phase 1, open-label study of DS-3032b to assess its safety and tolerability, identify a maximum tolerated dose (MTD)/tentative recommended phase 2 dose (RP2D), and assess its pharmacokinetic (PK)/ pharmacodynamic (PD) properties in subjects with advanced solid tumors or lymphomas. Approximately 5 US sites are planned for ...

Phase

4.05 miles

Learn More »